Dominant optic atrophy (original) (raw)

Abstract

Definition of the disease: Dominant Optic Atrophy (DOA) is a neuro-ophthalmic condition characterized by a bilateral degeneration of the optic nerves, causing insidious visual loss, typically starting during the first decade of life. The disease affects primary the retinal ganglion cells (RGC) and their axons forming the optic nerve, which transfer the visual information from the photoreceptors to the lateral geniculus in the brain. Epidemiology: The prevalence of the disease varies from 1/10000 in Denmark due to a founder effect, to 1/30000 in the rest of the world. Clinical description: DOA patients usually suffer of moderate visual loss, associated with central or paracentral visual field deficits and color vision defects. The severity of the disease is highly variable, the visual acuity ranging from normal to legal blindness. The ophthalmic examination discloses on fundoscopy isolated optic disc pallor or atrophy, related to the RGC death. About 20% of DOA patients harbour extraocular multi-systemic features, including neurosensory hearing loss, or less commonly chronic progressive external ophthalmoplegia, myopathy, peripheral neuropathy, multiple sclerosis-like illness, spastic paraplegia or cataracts. Aetiology: Two genes (OPA1, OPA3) encoding inner mitochondrial membrane proteins and three loci (OPA4, OPA5, OPA8) are currently known for DOA. Additional loci and genes (OPA2, OPA6 and OPA7) are responsible for X-linked or recessive optic atrophy. All OPA genes yet identified encode mitochondrial proteins embedded in the inner membrane and ubiquitously expressed, as are the proteins mutated in the Leber Hereditary Optic Neuropathy. OPA1 mutations affect mitochondrial fusion, energy metabolism, control of apoptosis, calcium clearance and maintenance of mitochondrial genome integrity. OPA3 mutations only affect the energy metabolism and the control of apoptosis. Diagnosis: Patients are usually diagnosed during their early childhood, because of bilateral, mild, otherwise unexplained visual loss related to optic discs pallor or atrophy, and typically occurring in the context of a family history of DOA. Optical Coherence Tomography further discloses non-specific thinning of retinal nerve fiber layer, but a normal morphology of the photoreceptors layers. Abnormal visual evoked potentials and pattern ERG may also reflect the dysfunction of the RGCs and their axons. Molecular diagnosis is provided by the identification of a mutation in the OPA1 gene (75% of DOA patients) or in the OPA3 gene (1% of patients). Prognosis: Visual loss in DOA may progress during puberty until adulthood, with very slow subsequent chronic progression in most of the cases. On the opposite, in DOA patients with associated extra-ocular features, the visual loss may be more severe over time. Management: To date, there is no preventative or curative treatment in DOA; severely visually impaired patients may benefit from low vision aids. Genetic counseling is commonly offered and patients are advised to avoid alcohol and tobacco consumption, as well as the use of medications that may interfere with mitochondrial metabolism. Gene and pharmacological therapies for DOA are currently under investigation.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (101)

  1. Kjer P: Infantile optic atrophy with dominant mode of inheritance: a clinical and genetic study of 19 Danish families. Acta Ophthalmol Suppl 1959, 164(Supp 54):1-147.
  2. Taban M, Cohen BH, David Rothner A, Traboulsi EI: Association of optic nerve hypoplasia with mitochondrial cytopathies. J Child Neurol 2006, 21 (11):956-960.
  3. Delettre C, Lenaers G, Pelloquin L, Belenguer P, Hamel CP: OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease. Mol Genet Metab 2002, 75(2):97-107.
  4. Amati-Bonneau P, Milea D, Bonneau D, Chevrollier A, Ferre M, Guillet V, Gueguen N, Loiseau D, de Crescenzo MA, Verny C, et al: OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol 2009, 41(10):1855-1865.
  5. Thiselton DL, Alexander C, Taanman JW, Brooks S, Rosenberg T, Eiberg H, Andreasson S, Van Regemorter N, Munier FL, Moore AT, et al: A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci 2002, 43
  6. Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L, Ah- Kine D, Hudson G, Czermin B, Taylor RW, et al: The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology 2010, 117(8):1531-1546.
  7. Ferre M, Bonneau D, Milea D, Chevrollier A, Verny C, Dollfus H, Ayuso C, Defoort S, Vignal C, Zanlonghi X, et al: Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 Novel OPA1 Mutations. Human Mutation 2009, 30(7):E692-E705.
  8. Toomes C, Marchbank NJ, Mackey DA, Craig JE, Newbury-Ecob RA, Bennett CP, Vize CJ, Desai SP, Black GC, Patel N, et al: Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy. Hum Mol Genet 2001, 10(13):1369-1378.
  9. Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, Toscano A, Musumeci O, Valentino ML, Caporali L, et al: Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010, 133(Pt 3):771-786.
  10. Batten B: A family suffering from hereditary optic atrophy. Trans Ophthalmol Soc UK 1896, 16:125.
  11. Snell S: Disease of the optic nerve I. hereditary or congenital optic atrophy and allied cases. Trans Ophthalmol Soc UK 1897, 17:66-81.
  12. Nettleship E: Bowman lecture: on some hereditary diseases of the eyes. Trans Ophthalmol Soc UK 1909, 29(57):116.
  13. Griscom J: Am J Ophthalmol 1921, 5:347.
  14. Voisin J, Delthil S: Bull Soc Opht France. 1949, 2.
  15. Carelli V, La Morgia C, Iommarini L, Carroccia R, Mattiazzi M, Sangiorgi S, Farne S, Maresca A, Foscarini B, Lanzi L, et al: Mitochondrial optic neuropathies: how two genomes may kill the same cell type? Bioscience Reports 2007, 27(1-3):173-184.
  16. Milea D, Amati-Bonneau P, Reynier P, Bonneau D: Genetically determined optic neuropathies. Curr Opin Neurol 2010, 23(1):24-28.
  17. Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF: Inherited mitochondrial optic neuropathies. J Med Genet 2009, 46(3):145-158.
  18. Kjer B, Eiberg H, Kjer P, Rosenberg T: Dominant optic atrophy mapped to chromosome 3q region. II. Clinical and epidemiological aspects. Acta Ophthalmol Scandinavica 1996, 74(1):3-7.
  19. Cohn AC, Toomes C, Hewitt AW, Kearns LS, Inglehearn CF, Craig JE, Mackey DA: The natural history of OPA1-related autosomal dominant optic atrophy. Br J Ophthalmol 2008, 92(10):1333-1336.
  20. Votruba M, Fitzke FW, Holder GE, Carter A, Bhattacharya SS, Moore AT: Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy. Arch Ophthalmol 1998, 116(3):351-358.
  21. Votruba M, Moore AT, Bhattacharya SS: Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy. Journal of J Med Genet 1998, 35(10):793-800.
  22. Barboni P, Carbonelli M, Savini G, Foscarini B, Parisi V, Valentino ML, Carta A, De Negri A, Sadun F, Zeviani M, et al: OPA1 mutations associated with dominant optic atrophy influence optic nerve head size. Ophthalmology 2011, 117(8):1547-1553.
  23. Yu-Wai-Man P, Bailie M, Atawan A, Chinnery PF, Griffiths PG: Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations. Eye (Lond) 2011, 25(5):596-602.
  24. Smith DP: Diagnostic criteria in cominantly inherited juvenile optic atrophy. A report of three new families. Am J Optom Physiol Opt Arch Am Acad Optom 1972, 49(3):183-200.
  25. Puomila A, Huoponen K, Mantyjarvi M, Hamalainen P, Paananen R, Sankila EM, Savontaus ML, Somer M, Nikoskelainen E: Dominant optic atrophy: correlation between clinical and molecular genetic studies. Acta Opthalmol Scandinavica 2005, 83(3):337-346.
  26. Bremner FD, Tomlin EA, Shallo-Hoffmann J, Votruba M, Smith SE: The pupil in dominant optic atrophy. Invest Ophthalmol Vis Sci 2001, 42(3):675-678.
  27. La Morgia C, Ross-Cisneros FN, Sadun AA, Hannibal J, Munarini A, Mantovani V, Barboni P, Cantalupo G, Tozer KR, Sancisi E, et al: Melanopsin retinal ganglion cells are resistant to neurodegeneration in mitochondrial optic neuropathies. Brain 2010, 133(Pt 8):2426-2438.
  28. Reynier P, Amati-Bonneau P, Verny C, Olichon A, Simard G, Guichet A, Bonnemains C, Malecaze F, Malinge MC, Pelletier JB, et al: OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. J Med Genet 2004, 41(9):e110.
  29. Cornille K, Milea D, Amati-Bonneau P, Procaccio V, Zazoun L, Guillet V, El Achouri G, Delettre C, Gueguen N, Loiseau D, et al: Reversible optic neuropathy with OPA1 exon 5b mutation. Ann Neurol 2008, 63(5):667-671.
  30. Nochez Y, Arsene S, Gueguen N, Chevrollier A, Ferre M, Guillet V, Desquiret V, Toutain A, Bonneau D, Procaccio V, et al: Acute and late-onset optic atrophy due to a novel OPA1 mutation leading to a mitochondrial coupling defect. Mol Vis 2009, 15:598-608.
  31. Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, Campos Y, Rivera H, de la Aleja JG, Carroccia R, et al: OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain 2008, 131(Pt 2):338-351.
  32. Hudson G, Amati-Bonneau P, Blakely EL, Stewart JD, He L, Schaefer AM, Griffiths PG, Ahlqvist K, Suomalainen A, Reynier P, et al: Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 2008, 131(Pt 2):329-337.
  33. Amati-Bonneau P, Guichet A, Olichon A, Chevrollier A, Viala F, Miot S, Ayuso C, Odent S, Arrouet C, Verny C, et al: OPA1 R445H mutation in optic atrophy associated with sensorineural deafness. Ann Neurol 2005, 58 (6):958-963.
  34. Amati-Bonneau P, Odent S, Derrien C, Pasquier L, Malthiery Y, Reynier P, Bonneau D: The association of autosomal dominant optic atrophy and moderate deafness may be due to the R445H mutation in the OPA1 gene. Am J Ophthalmol 2003, 136(6):1170-1171.
  35. Li C, Kosmorsky G, Zhang K, Katz BJ, Ge J, Traboulsi EI: Optic atrophy and sensorineural hearing loss in a family caused by an R445H OPA1 mutation. American journal of medical genetics 2005, 138A(3):208-211.
  36. Payne M, Yang Z, Katz BJ, Warner JE, Weight CJ, Zhao Y, Pearson ED, Treft RL, Hillman T, Kennedy RJ, et al: Dominant optic atrophy, sensorineural hearing loss, ptosis, and ophthalmoplegia: a syndrome caused by a missense mutation in OPA1. Am J Ophthalmol 2004, 138(5):749-755.
  37. Huang T, Santarelli R, Starr A: Mutation of OPA1 gene causes deafness by affecting function of auditory nerve terminals. Brain Res 2009, 1300:97- 104.
  38. Verny C, Loiseau D, Scherer C, Lejeune P, Chevrollier A, Gueguen N, Guillet V, Dubas F, Reynier P, Amati-Bonneau P, et al: Multiple sclerosis-like disorder in OPA1-related autosomal dominant optic atrophy. Neurology 2008, 70(13 Pt 2):1152-1153.
  39. Pretegiani E, Rufa A, Gallus GN, Cardaioli E, Malandrini A, Federico A: Spastic paraplegia in 'dominant optic atrophy plus' phenotype due to OPA1 mutation. Brain 2011, 134(Pt 11):e195.
  40. Marelli C, Amati-Bonneau P, Reynier P, Layet V, Layet A, Stevanin G, Brissaud E, Bonneau D, Durr A, Brice A: Heterozygous OPA1 mutations in Behr syndrome. Brain 2011, 134(Pt 4):e169.
  41. Schaaf CP, Blazo M, Lewis RA, Tonini RE, Takei H, Wang J, Wong LJ, Scaglia F: Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations. Mol Genet Metab 2011, 103(4):383-387.
  42. Eiberg H, Kjer B, Kjer P, Rosenberg T: Dominant optic atrophy (OPA1) mapped to chromosome 3q region. I. Linkage analysis.Hum Mol Genet 1994, 3(6):977-980.
  43. Bonneau D, Souied E, Gerber S, Rozet JM, D'Haens E, Journel H, Plessis G, Weissenbach J, Munnich A, Kaplan J: No evidence of genetic heterogeneity in dominant optic atrophy. J Med Genet 1995, 32(12):951- 953.
  44. Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, Rodriguez M, Kellner U, Leo-Kottler B, Auburger G, et al: OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nature Genet 2000, 26(2):211-215.
  45. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, et al: Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nature Genet 2000, 26(2):207-210.
  46. Kerrison JB, Arnould VJ, Ferraz Sallum JM, Vagefi MR, Barmada MM, Li Y, Zhu D, Maumenee IH: Genetic heterogeneity of dominant optic atrophy, Kjer type: Identification of a second locus on chromosome 18q12.2-12.3. Arch Ophthalmol 1999, 117(6):805-810.
  47. Barbet F, Hakiki S, Orssaud C, Gerber S, Perrault I, Hanein S, Ducroq D, Dufier JL, Munnich A, Kaplan J, et al: A third locus for dominant optic atrophy on chromosome 22q. J Med Genet 2005, 42(1):e1.
  48. Assink JJ, Tijmes NT, ten Brink JB, Oostra RJ, Riemslag FC, de Jong PT, Bergen AA: A gene for X-linked optic atrophy is closely linked to the Xp11.4-Xp11.2 region of the X chromosome. Am J Hum Genet 1997, 61 (4):934-939.
  49. Katz BJ, Zhao Y, Warner JE, Tong Z, Yang Z, Zhang K: A family with X-linked optic atrophy linked to the OPA2 locus Xp11.4-Xp11.2. American Am J Med Genet 2006, 140(20):2207-2211.
  50. Barbet F, Gerber S, Hakiki S, Perrault I, Hanein S, Ducroq D, Tanguy G, Dufier JL, Munnich A, Rozet JM, et al: A first locus for isolated autosomal recessive optic atrophy (ROA1) maps to chromosome 8q. Eur J Hum Genet 2003, 11(12):966-971.
  51. Hanein S, Perrault I, Roche O, Gerber S, Khadom N, Rio M, Boddaert N, Jean- Pierre M, Brahimi N, Serre V, et al: TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-recessive nonsyndromic optic atrophy. Am J Hum Genet 2009, 84(4):493-498.
  52. Anikster Y, Kleta R, Shaag A, Gahl WA, Elpeleg O: Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum Genet 2001, 69(6):1218-1224.
  53. Carelli V, Schimpf S, Fuhrmann N, Valentino ML, Zanna C, Iommarini L, Papke M, Schaich S, Tippmann S, Baumann B, et al: A clinically complex form of dominant optic atrophy (OPA8) maps on chromosome 16. Hum Mol Genet 2011, 20(10):1893-905.
  54. Da Cruz S, Xenarios I, Langridge J, Vilbois F, Parone PA, Martinou JC: Proteomic analysis of the mouse liver mitochondrial inner membrane. J Biol Chem 2003, 278(42):41566-41571.
  55. Olichon A, Emorine LJ, Descoins E, Pelloquin L, Brichese L, Gas N, Guillou E, Delettre C, Valette A, Hamel CP, et al: The human dynamin-related protein OPA1 is anchored to the mitochondrial inner membrane facing the inter-membrane space. FEBS letters 2002, 523(1-3):171-176.
  56. Pierron D, Ferre M, Rocher C, Chevrollier A, Murail P, Thoraval D, Amati- Bonneau P, Reynier P, Letellier T: OPA1-related dominant optic atrophy is not strongly influenced by mitochondrial DNA background. Med Genet 2009, 10:70.
  57. Chevrollier A, Guillet V, Loiseau D, Gueguen N, de Crescenzo MA, Verny C, Eng MF, Dollfus H, Odent S, Milea D, et al: Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann Neurol 2008, 63 (6):794-798.
  58. Olichon A, Landes T, Arnaune-Pelloquin L, Emorine LJ, Mils V, Guichet A, Delettre C, Hamel C, Amati-Bonneau P, Bonneau D, et al: Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis. J Cell Physiol 2007, 211(2):423-430.
  59. Zanna C, Ghelli A, Porcelli AM, Karbowski M, Youle RJ, Schimpf S, Wissinger B, Pinti M, Cossarizza A, Vidoni S, et al: OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 2008, 131(Pt 2):352-367.
  60. Lenaers G, Reynier P, Elachouri G, Soukkarieh C, Olichon A, Belenguer P, Baricault L, Ducommun B, Hamel C, Delettre C: OPA1 functions in mitochondria and dysfunctions in optic nerve. Int J Biochem Cell Biol 2009, 41(10):1866-1874.
  61. Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, Lenaers G: Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem 2003, 278(10):7743-7746.
  62. Griparic L, van der Wel NN, Orozco IJ, Peters PJ, van der Bliek AM: Loss of the intermembrane space protein Mgm1/OPA1 induces swelling and localized constrictions along the lengths of mitochondria. J Biol Chem 2004, 279(18):18792-18798.
  63. Elachouri G, Vidoni S, Zanna C, Pattyn A, Boukhaddaoui H, Gaget K, Yu-Wai- Man P, Gasparre G, Sarzi E, Delettre C, et al: OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res 2011, 21(1):12-20.
  64. Olichon A, Elachouri G, Baricault L, Delettre C, Belenguer P, Lenaers G: OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis. Cell Death Differ 2007, 14(4):682-692.
  65. Dayanithi G, Chen-Kuo-Chang M, Viero C, Hamel C, Muller A, Lenaers G: Characterization of Ca2+ signalling in postnatal mouse retinal ganglion cells: involvement of OPA1 in Ca2+ clearance. Ophthalmic Genet 2010, 31 (2):53-65.
  66. Spinazzi M, Cazzola S, Bortolozzi M, Baracca A, Loro E, Casarin A, Solaini G, Sgarbi G, Casalena G, Cenacchi G, et al: A novel deletion in the gtpase domain of OPA1 causes defects in mitochondrial morphology and distribution, but not in function. Hum Mol Genet. 2008, 17(21):3291-3302
  67. Yu-Wai-Man P, Trenell MI, Hollingsworth KG, Griffiths PG, Chinnery PF: OPA1 mutations impair mitochondrial function in both pure and complicated dominant optic atrophy. Brain 2010.
  68. Andrews RM, Griffiths PG, Johnson MA, Turnbull DM: Histochemical localisation of mitochondrial enzyme activity in human optic nerve and retina. Br J Ophthalmol 1999, 83(2):231-235.
  69. Bristow EA, Griffiths PG, Andrews RM, Johnson MA, Turnbull DM: The distribution of mitochondrial activity in relation to optic nerve structure. Arch Ophthalmol 2002, 120(6):791-796.
  70. Wang L, Dong J, Cull G, Fortune B, Cioffi GA: Varicosities of intraretinal ganglion cell axons in human and nonhuman primates. Invest Ophthalmol Vis Sci 2003, 44(1):2-9.
  71. Yu Wai Man CY, Chinnery PF, Griffiths PG: Optic neuropathies--importance of spatial distribution of mitochondria as well as function. Medical hypotheses 2005, 65(6):1038-1042.
  72. Osborne NN, Li GY, Ji D, Mortiboys HJ, Jackson S: Light affects mitochondria to cause apoptosis to cultured cells: possible relevance to ganglion cell death in certain optic neuropathies. J Neurochem 2008, 105 (5):2013-2028.
  73. Alavi MV, Bette S, Schimpf S, Schuettauf F, Schraermeyer U, Wehrl HF, Ruttiger L, Beck SC, Tonagel F, Pichler BJ, et al: A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain 2007, 130(Pt 4):1029-1042.
  74. Davies VJ, Hollins AJ, Piechota MJ, Yip W, Davies JR, White KE, Nicols PP, Boulton ME, Votruba M: Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet 2007, 16(11):1307-1318.
  75. Heiduschka P, Schnichels S, Fuhrmann N, Hofmeister S, Schraermeyer U, Wissinger B, Alavi MV: Electrophysiological and histologic assessment of retinal ganglion cell fate in a mouse model for OPA1-associated autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci 2010, 51 (3):1424-1431.
  76. Barnard AR, Charbel Issa P, Perganta G, Williams PA, Davies VJ, Sekaran S, Votruba M, Maclaren RE: Specific deficits in visual electrophysiology in a mouse model of dominant optic atrophy. Exp Eye Res 2011, 93(5):771-77.
  77. Williams PA, Morgan JE, Votruba M: Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy. Brain 2010, 133(10):2942-51.
  78. White KE, Davies V, Hogan V, Piechota M, Nichols P, Turnbull DM, Votruba M: OPA1 deficiency is associated with increased autophagy in retinal ganglion cells in a murine model of dominant optic atrophy. Invest Ophthalmol Vis Sci 2009, 50(6):2567-2571.
  79. Alavi MV, Fuhrmann N, Nguyen HP, Yu-Wai-Man P, Heiduschka P, Chinnery PF, Wissinger B: Subtle neurological and metabolic abnormalities in an Opa1 mouse model of autosomal dominant optic atrophy. Exp Neurol 2009, 220(2):404-409.
  80. Votruba M, Thiselton D, Bhattacharya SS: Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy. Br J Ophthalmol 2003, 87(1):48-53.
  81. Milea D, Sander B, Wegener M, Jensen H, Kjer B, Jorgensen TM, Lund-Andersen H, Larsen M: Axonal loss occurs early in dominant optic atrophy. Acta Ophthalmol 2010, 88(3):342-346.
  82. Alward WL: The OPA1 gene and optic neuropathy. Br J Ophthalmol 2003, 87(1):2-3.
  83. Holder GE, Votruba M, Carter AC, Bhattacharya SS, Fitzke FW, Moore AT: Electrophysiological findings in dominant optic atrophy (DOA) linking to the OPA1 locus on chromosome 3q 28-qter. Doc Ophthalmol 1998, 95(3-4):217-228.
  84. Fuhrmann N, Alavi MV, Bitoun P, Woernle S, Auburger G, Leo-Kottler B, Yu- Wai-Man P, Chinnery P, Wissinger B: Genomic rearrangements in OPA1 are frequent in patients with autosomal dominant optic atrophy. J Med Genet 2009, 46(2):136-144.
  85. Fuhrmann N, Schimpf S, Kamenisch Y, Leo-Kottler B, Alexander C, Auburger G, Zrenner E, Wissinger B, Alavi MV: Solving a 50 year mystery of a missing OPA1 mutation: more insights from the first family diagnosed with autosomal dominant optic atrophy. Mol Neurodegener 2010, 5:25.
  86. Almind GJ, Gronskov K, Milea D, Larsen M, Brondum-Nielsen K, Ek J: Genomic deletions in OPA1 in Danish patients with autosomal dominant optic atrophy. BMC Med Genet 2011, 12(1):49.
  87. Yu-Wai-Man P, Stewart JD, Hudson G, Andrews RM, Griffiths PG, Birch MK, Chinnery PF: OPA1 increases the risk of normal but not high tension glaucoma. J Med Genet 2010, 47(2):120-125.
  88. Volker-Dieben HJ, Went LN, de Vries-de Mol EC: Comparative colour vision and other ophthalmological studies in three families with dominant inherited juvenile optic atrophy. Mod Probl Ophthalmol 1974, 13(0):277-281.
  89. Went LN, De Vries-De Mol EC, Volker-Dieben HJ: A family with apparently sex-linked optic atrophy. J Med Genet 1975, 12(1):94-98.
  90. Yu-Wai-Man P, Griffiths PG, Chinnery PF: Mitochondrial optic neuropathies - Disease mechanisms and therapeutic strategies. Prog Retin Eye Res 2010, 30(2):81-114.
  91. Barrett TG, Bundey SE: Wolfram (DIDMOAD) syndrome. J Med Genet 1997, 34(10):838-841.
  92. Barrett TG, Bundey SE, Fielder AR, Good PA: Optic atrophy in Wolfram (DIDMOAD) syndrome. Eye (Lond) 1997, 11(Pt 6):882-888.
  93. Eiberg H, Hansen L, Kjer B, Hansen T, Pedersen O, Bille M, Rosenberg T, Tranebjaerg L: Autosomal dominant optic atrophy associated with hearing impairment and impaired glucose regulation caused by a missense mutation in the WFS1 gene. J Med Genet 2006, 43(5):435-440.
  94. Rendtorff ND, Lodahl M, Boulahbel H, Johansen IR, Pandya A, Welch KO, Norris VW, Arnos KS, Bitner-Glindzicz M, Emery SB, et al: Identification of p. A684V missense mutation in the WFS1 gene as a frequent cause of autosomal dominant optic atrophy and hearing impairment. Am J Med Genet 2011, 155A(6):1298-1313.
  95. Kleta R, Skovby F, Christensen E, Rosenberg T, Gahl WA, Anikster Y: 3-Methylglutaconic aciduria type III in a non-Iraqi-Jewish kindred: clinical and molecular findings. Mol Genet Metab 2002, 76(3):201-206.
  96. Voo I, Allf BE, Udar N, Silva-Garcia R, Vance J, Small KW: Hereditary motor and sensory neuropathy type VI with optic atrophy. Am J Ophthalmol 2003, 136(4):670-677.
  97. Zuchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S, Hamilton SR, Van Stavern G, Krajewski KM, Stajich J, et al: Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 2006, 59(2):276-281.
  98. Rouzier C, Bannwarth S, Chaussenot A, Chevrollier A, Verschueren A, Bonello-Palot N, Fragaki K, Cano A, Pouget J, Pellissier JF, et al: The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy 'plus' phenotype. Brain 2012, 135:23-34.
  99. Tranebjaerg L, Schwartz C, Eriksen H, Andreasson S, Ponjavic V, Dahl A, Stevenson RE, May M, Arena F, Barker D, et al: A new X linked recessive deafness syndrome with blindness, dystonia, fractures, and mental deficiency is linked to Xq22. J Med Genet 1995, 32(4):257-263.
  100. Jin H, May M, Tranebjaerg L, Kendall E, Fontan G, Jackson J, Subramony SH, Arena F, Lubs H, Smith S, et al: A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat Genet 1996, 14(2):177-180.
  101. Milone M, Younge BR, Wang J, Zhang S, Wong LJ: Mitochondrial disorder with OPA1 mutation lacking optic atrophy. Mitochondrion 2009, 9(4):279-281. doi:10.1186/1750-1172-7-46 Cite this article as: Lenaers et al.: Dominant optic atrophy. Orphanet Journal of Rare Diseases 2012 7:46.